This comes just weeks after Lupin secured USFDA approval for its Risperidone Injectable, used to treat schizophrenia and ...

Lupin shares have gained for eight consecutive trading sessions as of Tuesday's close. The last time the stock gained for eight consecutive sessions was between December 23, 2024 to January 1, 2025.

Mumbai: Lupin has announced that the U.S. Food and Drugs Administration (USFDA) has closed the inspection with six ...

Risperidone Injectable is the bioequivalent to the reference listed drug (RLD), Risperdal Consta Long-Acting Injection. It is ...

Lupin Manufacturing Solutions has announced that Empagliflozin API, manufactured at its Vizag facility, has received CADIFA ...

Sun Pharma and Lupin pursue regulatory approval for oral weight-loss drugs, potentially reshaping treatment access.

The market may consolidate, but overall, the trend remains favourable for bulls. Below are some short-term trading ideas to ...

The market may remain consolidative with rangebound trading until the August high is decisively broken. Below are some ...

The medicine had estimated annual sales of $190 million in the US, Lupin said, citing IQVIA moving annual toal July 2025 data ...

Lupin’s shares rose 2.8% in afternoon trading after the company received a key U.S. Food and Drug Administration (FDA) ...

Lupin receives USFDA approval for generic risperidone extended-release injectable suspension. Treatment for schizophrenia and ...

Global brokerage Investec upgraded Lupin to a ‘buy’ from the previous ‘hold’ and also lifted its price target by 8% to ₹2,265. The revised target implies a potential upside of about 14% from ...